Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update databaseJakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
European Urology Open Science|January 13, 2025
An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER ConsortiumSebastiaan Remmers, Katharina Beyer, Tariq A Lalmahomed, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
European Urology|November 14, 2019
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized TrialsAmar U Kishan, Fang-I Chu, Christopher R King, et al.
The Lancet. Oncology|September 8, 2018
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic reviewMadeline Pe, Lien Dorme, Corneel Coens, et al.
BMJ Open|April 5, 2022
Diagnostic and prognostic factors in patients with prostate cancer: a systematic reviewKatharina Beyer, Lisa Moris, Michael Lardas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
The Lancet. Oncology|February 3, 2020
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL ConsortiumCorneel Coens, Madeline Pe, Amylou C Dueck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update databaseJakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
European Urology Open Science|January 13, 2025
An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER ConsortiumSebastiaan Remmers, Katharina Beyer, Tariq A Lalmahomed, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
European Urology|November 14, 2019
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized TrialsAmar U Kishan, Fang-I Chu, Christopher R King, et al.
The Lancet. Oncology|September 8, 2018
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic reviewMadeline Pe, Lien Dorme, Corneel Coens, et al.
BMJ Open|April 5, 2022
Diagnostic and prognostic factors in patients with prostate cancer: a systematic reviewKatharina Beyer, Lisa Moris, Michael Lardas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
The Lancet. Oncology|February 3, 2020
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL ConsortiumCorneel Coens, Madeline Pe, Amylou C Dueck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
Pageof 16